Mn Services Vermogensbeheer B.V. Has $6.07 Million Position in Revvity, Inc. (NYSE:RVTY)

Mn Services Vermogensbeheer B.V. cut its position in shares of Revvity, Inc. (NYSE:RVTY) by 2.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,500 shares of the company’s stock after selling 1,200 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Revvity were worth $6,068,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. UniSuper Management Pty Ltd lifted its holdings in Revvity by 505.2% during the 1st quarter. UniSuper Management Pty Ltd now owns 9,864 shares of the company’s stock valued at $1,036,000 after purchasing an additional 8,234 shares during the last quarter. Entropy Technologies LP bought a new stake in shares of Revvity during the 1st quarter worth about $480,000. Jane Street Group LLC grew its stake in Revvity by 516.4% in the 1st quarter. Jane Street Group LLC now owns 453,343 shares of the company’s stock valued at $47,601,000 after buying an additional 379,802 shares during the last quarter. Quadrature Capital Ltd bought a new position in Revvity in the 1st quarter valued at about $1,267,000. Finally, Assenagon Asset Management S.A. lifted its position in Revvity by 3,171.3% during the second quarter. Assenagon Asset Management S.A. now owns 87,180 shares of the company’s stock worth $9,142,000 after acquiring an additional 84,515 shares during the last quarter. 86.65% of the stock is owned by institutional investors.

Revvity Trading Down 0.9 %

Shares of RVTY stock opened at $124.86 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.27. Revvity, Inc. has a fifty-two week low of $82.17 and a fifty-two week high of $129.50. The company has a market cap of $15.40 billion, a PE ratio of 90.48, a P/E/G ratio of 3.34 and a beta of 1.05. The stock’s fifty day moving average price is $121.60 and its two-hundred day moving average price is $114.54.

Revvity (NYSE:RVTY) last released its earnings results on Monday, November 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.15. The firm had revenue of $684.10 million for the quarter, compared to analysts’ expectations of $679.66 million. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.18 earnings per share. Equities analysts predict that Revvity, Inc. will post 4.75 EPS for the current fiscal year.

Revvity announced that its board has authorized a share buyback program on Monday, November 4th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 6.5% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Investors of record on Friday, January 17th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.22%. The ex-dividend date of this dividend is Friday, January 17th. Revvity’s payout ratio is 20.29%.

Insider Buying and Selling at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 2,153 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the sale, the insider now owns 23,960 shares of the company’s stock, valued at approximately $2,925,276.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Tajinder S. Vohra sold 2,153 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $122.09, for a total transaction of $262,859.77. Following the sale, the insider now owns 23,960 shares of the company’s stock, valued at $2,925,276.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Tajinder S. Vohra sold 2,154 shares of the company’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $121.73, for a total value of $262,206.42. Following the completion of the transaction, the insider now directly owns 19,652 shares of the company’s stock, valued at approximately $2,392,237.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

RVTY has been the topic of several research reports. Sanford C. Bernstein decreased their target price on Revvity from $150.00 to $145.00 and set an “outperform” rating on the stock in a research report on Tuesday. Robert W. Baird increased their price objective on Revvity from $136.00 to $138.00 and gave the stock an “outperform” rating in a research report on Tuesday. Raymond James lifted their target price on Revvity from $144.00 to $146.00 and gave the stock an “outperform” rating in a report on Tuesday. JPMorgan Chase & Co. upped their price target on shares of Revvity from $105.00 to $120.00 and gave the company a “neutral” rating in a research note on Tuesday, July 30th. Finally, Wells Fargo & Company assumed coverage on shares of Revvity in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price objective for the company. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Revvity presently has an average rating of “Moderate Buy” and an average price target of $132.07.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.